3,069 Shares in Henry Schein, Inc. (NASDAQ:HSIC) Bought by Cypress Capital Group

Cypress Capital Group purchased a new stake in Henry Schein, Inc. (NASDAQ:HSIC) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 3,069 shares of the company’s stock, valued at approximately $224,000.

Several other hedge funds and other institutional investors have also made changes to their positions in HSIC. Cromwell Holdings LLC increased its holdings in Henry Schein by 93.4% in the third quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock valued at $26,000 after buying an additional 170 shares during the last quarter. Summit Securities Group LLC acquired a new position in shares of Henry Schein during the 2nd quarter worth about $31,000. Beach Investment Counsel Inc. PA purchased a new position in shares of Henry Schein in the 2nd quarter valued at about $37,000. Blue Trust Inc. raised its position in shares of Henry Schein by 104.2% during the 2nd quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after acquiring an additional 475 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Henry Schein by 58.9% during the third quarter. Farther Finance Advisors LLC now owns 933 shares of the company’s stock worth $68,000 after purchasing an additional 346 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

HSIC stock opened at $73.91 on Friday. Henry Schein, Inc. has a 12-month low of $63.67 and a 12-month high of $82.63. The company has a market cap of $9.21 billion, a price-to-earnings ratio of 30.41, a PEG ratio of 2.15 and a beta of 0.87. The firm has a 50 day moving average of $70.68 and a 200-day moving average of $69.69. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. During the same period in the previous year, the firm posted $1.32 earnings per share. The business’s revenue for the quarter was up .4% compared to the same quarter last year. As a group, equities analysts expect that Henry Schein, Inc. will post 4.78 EPS for the current fiscal year.

Insider Activity at Henry Schein

In related news, COO Michael S. Ettinger sold 12,240 shares of Henry Schein stock in a transaction on Monday, November 18th. The stock was sold at an average price of $75.00, for a total value of $918,000.00. Following the transaction, the chief operating officer now owns 87,706 shares in the company, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the transaction, the senior vice president now directly owns 71,833 shares in the company, valued at approximately $4,978,026.90. This trade represents a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Evercore ISI increased their price target on shares of Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. Robert W. Baird cut their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Barrington Research restated an “outperform” rating and issued a $82.00 price objective on shares of Henry Schein in a research note on Wednesday, November 6th. UBS Group dropped their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Finally, StockNews.com raised Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Henry Schein currently has an average rating of “Moderate Buy” and a consensus target price of $78.89.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.